Organogenesis (NASDAQ:ORGO) Now Covered by Truist Financial

Stock analysts at Truist Financial initiated coverage on shares of Organogenesis (NASDAQ:ORGO) in a research report issued on Thursday,Benzinga reports. The brokerage set a “hold” rating and a $3.00 price target on the stock. Truist Financial’s price target points to a potential upside of 12.78% from the company’s current price.

Several other research analysts have also recently commented on the stock. Weiss Ratings cut shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wall Street Zen cut shares of Organogenesis from a “buy” rating to a “sell” rating in a report on Saturday, May 9th. Finally, BTIG Research cut shares of Organogenesis from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Organogenesis currently has an average rating of “Hold” and an average target price of $6.67.

Organogenesis Stock Performance

Shares of ORGO stock opened at $2.66 on Thursday. The firm has a 50 day moving average price of $2.44 and a two-hundred day moving average price of $3.73. The company has a quick ratio of 3.16, a current ratio of 3.53 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $342.29 million, a PE ratio of -14.00 and a beta of 1.31. Organogenesis has a 12-month low of $2.04 and a 12-month high of $7.08.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.08). The company had revenue of $37.23 million for the quarter, compared to analyst estimates of $43.26 million. Organogenesis had a positive return on equity of 9.63% and a negative net margin of 0.84%.

Insider Transactions at Organogenesis

In other news, Director Michael Joseph Driscoll acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were acquired at an average cost of $2.67 per share, with a total value of $26,700.00. Following the completion of the purchase, the director directly owned 225,707 shares of the company’s stock, valued at $602,637.69. The trade was a 4.64% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 33.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Quarry LP bought a new stake in shares of Organogenesis during the third quarter worth $25,000. Flagship Harbor Advisors LLC bought a new stake in shares of Organogenesis during the fourth quarter worth $34,000. Federated Hermes Inc. grew its stake in shares of Organogenesis by 52.8% during the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after buying an additional 2,953 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Organogenesis during the fourth quarter worth $57,000. Finally, Walleye Capital LLC bought a new stake in shares of Organogenesis during the second quarter worth $45,000. 49.57% of the stock is owned by institutional investors.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.